Pfizer Inc. (NYSE:PFE) Shares Sold by Hudson Valley Investment Advisors Inc. ADV

Hudson Valley Investment Advisors Inc. ADV trimmed its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 76.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,392 shares of the biopharmaceutical company's stock after selling 119,705 shares during the quarter. Hudson Valley Investment Advisors Inc. ADV's holdings in Pfizer were worth $922,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Impact Capital Partners LLC grew its stake in Pfizer by 26.5% during the 1st quarter. Impact Capital Partners LLC now owns 13,686 shares of the biopharmaceutical company's stock worth $347,000 after purchasing an additional 2,864 shares in the last quarter. Pitti Group Wealth Management LLC grew its stake in Pfizer by 7.5% during the 1st quarter. Pitti Group Wealth Management LLC now owns 15,186 shares of the biopharmaceutical company's stock worth $385,000 after purchasing an additional 1,060 shares in the last quarter. SeaCrest Wealth Management LLC grew its stake in Pfizer by 4.2% during the 1st quarter. SeaCrest Wealth Management LLC now owns 68,330 shares of the biopharmaceutical company's stock worth $1,731,000 after purchasing an additional 2,740 shares in the last quarter. Procyon Advisors LLC grew its stake in Pfizer by 41.4% during the 1st quarter. Procyon Advisors LLC now owns 78,591 shares of the biopharmaceutical company's stock worth $1,954,000 after purchasing an additional 23,020 shares in the last quarter. Finally, Next Level Private LLC boosted its position in shares of Pfizer by 31.3% during the 1st quarter. Next Level Private LLC now owns 56,877 shares of the biopharmaceutical company's stock worth $1,441,000 after acquiring an additional 13,543 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Up 1.0%

Pfizer stock opened at $23.36 on Friday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market capitalization of $132.81 billion, a P/E ratio of 16.57, a PEG ratio of 0.64 and a beta of 0.57. The stock has a 50-day simple moving average of $22.95 and a 200-day simple moving average of $25.00.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm's revenue was down 7.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.82 EPS. Equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.36%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio is presently 124.64%.

Analyst Ratings Changes

Several research firms have recently issued reports on PFE. Cantor Fitzgerald began coverage on Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.